“Ecobiotics: A Novel Approach to Recurrent C. difficile infections”
Tuesday, February 23rd — Live Broadcast
PODCAST IS NOW AVAILABLE, PLEASE CLICK ON THE SERES THERAPEUTICS LOGO BELOW
10 a.m. Pacific Time,, 11 a.m. Mountain Time,
12 p.m. Central Time, 1 p.m. Eastern Time
We invite you to listen to the live broadcast and archived programs by clicking on the
Cdiff radio logo displayed below:
This episode introduces Seres Therapeutics, a leading microbiome therapeutics company, which recently published in the Journal of Infectious Diseases positive results from an open-label Phase 1b/2 study of SER-109 for the treatment of patients with recurrent
C. difficile infections (CDI). Seres Therapeutics is creating a new class of medicines to treat diseases resulting from functional deficiencies in the microbiome, a condition known as dysbiosis.
TO LISTEN TO THIS EPISODE – PLEASE CLICK ON THE SERES THERAPEUTICS LOGO BELOW
New insights into the human microbiome are fundamentally reshaping how we understand and treat a wide range of diseases, creating new possibilities for patients not served by current therapeutic approaches. Ecobiotics are ecological compositions of beneficial organisms that are designed to reestablish a healthy microbiome. The discovery efforts at Seres Therapeutics currently span metabolic, inflammatory, and infectious diseases.
Dr. David Cook, Ph.D., Executive Vice President of R&D and Chief Scientific Officer
Dr. Michele (Shelley) Trucksis, Ph.D., M.D., Executive Vice President and Chief Medical Officer
As we discuss the microbiome, CDI, clinical studies SER-109, Probiotics, ECOSPOR, and much more
Seres Therapeutics Disclaimer:
“This interview will include forward-looking statements on Seres Therapeutics’ current expectations and projections about future events. These statements are based upon current beliefs, expectations and assumptions, and are subject to a number of important risks and uncertainties, including those set forth in Seres Therapeutics’ filings with the SEC, many of which are difficult to predict. Actual results may differ materially from such statements. The information included in this interview is provided only as of the date of this interview, and Seres Therapeutics undertakes no obligation to update any forward-looking statements stated in this interview on account of new information, future events, or otherwise, except as required by law. Seres Therapeutics has provided financial support to the C Diff Foundation.”